Expression of eukaryotic initiation factor 4E and 4E binding protein 1 in colorectal carcinogenesis

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 1, 2015, Pages 404-413

  Diab Assaf, Mona ^a   Abou khouzam, Raefa ^a   Saadallah Zeidan, Nina ^a   Habib, Khaled ^b   Bitar, Nizar ^a   Karam, Walid ^a   Liagre, Bertrand ^c   Harakeh, Steve ^d   Azar, Rania ^a  

^a LEBANESE UNIVERSITY   (Lebanon)

^b Specialized Medical Laboratory   (Lebanon)

^c UNIVERSITÉ DE LIMOGES   (France)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

4E BP1; Colorectal cancer; eIF4E; Immunuhistochemistry; Translational control

Indexed keywords

EIF4EBP1 PROTEIN, HUMAN; INITIATION FACTOR 4E; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADENOCARCINOMA; ADENOMA; CANCER GRADING; CARCINOGENESIS; COLON; COLORECTAL TUMOR; DISEASE COURSE; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ADENOMA; CARCINOGENESIS; COLON; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; EUKARYOTIC INITIATION FACTOR-4E; HUMANS; NEOPLASM GRADING; PHOSPHOPROTEINS; PHOSPHORYLATION;

EID: 84923114940     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics 2014. CA Cancer J Clin 2014; 64: 104-117.
2. Merrick WC and Harris ME. Control not at initiation? Bah, humbug! EMBO J 2014; 33: 3-4.
3. Martineau Y, Azar R, Bousquet C, Pyronnet S. Anti-oncogenic potential of the eIF4E-binding proteins. Oncogene 2013; 32: 671-6777.
4. Hsieh AC and Ruggero D. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res 2010; 16: 4914-4920.
5. Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB, Polunovsky VA. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004; 5: 553-563.
6. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, Pandolfi PP. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004; 10: 484-486.
7. Hou J, Lam F, Proud C, Wang S. Targeting Mnks for cancer therapy. Oncotarget 2012; 3: 118-131.
8. Hamilton S and Aaltonen L. Pathology and Genetics of Tumours of the Digestive System. World Health Organization Classification of Tumours International Agency for Research on Cancer (IARC). IARC Press; 2000. Lyon.
9. Martineau Y, Azar R, Müller D, Lasfargues C, El Khawand S, Anesia R, Pelletier J, Bousquet C, Pyronnet S. Pancreatic tumours escape from translational control through 4E-BP1 loss. Oncogene 2014; 33: 1367-1374.
10. Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013; 14: 16365-16385.
11. Markowitz SD and Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-2460.
12. Rosenwald IB, Chen JJ, Wang S, Savas L, London IM, Pullman J. Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 1999; 18: 2507-2517.
13. Berkel HJ, Turbat-Herrera EA, Shi R, de Benedetti A. Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon. Cancer Epidemiol Biomarkers Prev 2001; 10: 663-666.
14. Nathan CO, Franklin S, Abreo FW, Nassar R, De Benedetti A, Glass J. Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. J Clin Oncol 1999; 17: 2909-2914.
15. Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS, McNulty AM, Parsons SH, Brail LH, Colligan BM, Koop JW, Hurst BM, Deddens JA, Neubauer BL, Stancato LF, Carter HW, Douglass LE, Carter JH. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 2009; 69: 3866-3873.
16. Seki N, Takasu T, Mandai K, Nakata M, Saeki H, Heike Y, Takata I, Segawa Y, Hanafusa T, Eguchi K. Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clin Cancer Res 2002; 8: 3046-3053.
17. Sorrells DL, Meschonat C, Black D, Li BD. Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor. J Surg Res 1999; 85: 37-42.
18. Culjkovic B and Borden KL. Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer. J Oncol 2009; 2009: 981679.
19. Topisirovic I, Siddiqui N, Orolicki S, Skrabanek LA, Tremblay M, Hoang T, Borden KL. Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and this activity is dysregulated in cancer. Mol Cell Biol 2009; 29: 1152-1162.
20. López de Silanes I, Fan J, Yang X, Zonderman AB, Potapova O, Pizer ES, Gorospe M. Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene 2003; 22: 7146-7154.
21. DeFatta RJ, Turbat-Herrera EA, Li BD, Anderson W, De Benedetti A. Elevated expression of eIF4E in confined early breast cancer lesions: possible role of hypoxia. Int J Cancer 1999; 80: 516-522.
22. Yi T, Papadopoulos E, Hagner PR, Wagner G. Hypoxia-inducible factor-1a (HIF-1a) promotes cap-dependent translation of selective mRNAs through up-regulating initiation factor eIF4E1 in breast cancer cells under hypoxia conditions. J Biol Chem 2013; 288: 18732-18742.
23. Fan S, Ramalingam SS, Kauh J, Xu Z, Khuri FR, Sun SY. Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol Ther 2009; 8: 1463-1469.
24. Scheper GC, Proud CG. Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation? Eur J Biochem 2002; 269: 5350-5359.
25. Diab S, Kumarasiri M, Yu M, Teo T, Proud C, Milne R, Wang S. MAP Kinase-Interacting Kinases-Emerging Targets against Cancer. Chem Biol 2014; 21: 441-452.
26. Slepenkov SV, Darzynkiewicz E, Rhoads RE. Stopped-flow kinetic analysis of eIF4E and phosphorylated eIF4E binding to cap analogs and capped oligoribonucleotides: evidence for a one-step binding mechanism. J Biol Chem 2006; 281: 14927-14938.
27. McKendrick L, Morley SJ, Pain VM, Jagus R, Joshi B. Phosphorylation of eukaryotic initiation factor 4E (eIF4E) at Ser209 is not required for protein synthesis in vitro and in vivo. Eur J Biochem 2001; 268: 5375-5385.
28. Martín ME, Pérez MI, Redondo C, Alvarez MI, Salinas M, Fando JL. 4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. Int J Biochem Cell Biol 2000; 32: 633-642.
29. Rojo F, Najera L, Lirola J, Jiménez J, Guzmán M, Sabadell MD, Baselga J, Ramon y Cajal S. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 2007; 13: 81-89.
30. Coleman LJ, Peter MB, Teall TJ, Brannan RA, Hanby AM, Honarpisheh H, Shaaban AM, Smith L, Speirs V, Verghese ET, McElwaine JN, Hughes TA. Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer 2009; 100: 1393-1399.
31. Castellvi J, Garcia A, Ruiz-Marcellan C, Hernández-Losa J, Peg V, Salcedo M, Gil-Moreno A, Ramon y Cajal S. Cell signaling in endometrial carcinoma: phosphorylated 4E- binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis. Hum Pathol 2009; 40: 1418-1426.
32. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, Ramon y Cajal S. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006; 107: 1801-1811.
33. Yamaguchi S, Ishihara H, Yamada T, Tamura A, Usui M, Tominaga R, Munakata Y, Satake C, Katagiri H, Tashiro F, Aburatani H, Tsukiyama-Kohara K, Miyazaki J, Sonenberg N, Oka Y. ATF4-mediated induction of 4E-BP1 contributes to pancreatic beta cell survival under endoplasmic reticulum stress. Cell Metab 2008; 7: 269-276.
34. Tettweiler G, Miron M, Jenkins M, Sonenberg N, Lasko PF. Starvation and oxidative stress resistance in Drosophila are mediated through the eIF4E-binding protein, d4E-BP. Genes Dev 2005; 19: 1840-1843.
35. Azar R, Lasfargues C, Bousquet C, Pyronnet S. Contribution of HIF-1α in 4E-BP1 gene expression. Mol Cancer Res 2013; 11: 54-61.
36. Azar R, Susini C, Bousquet C, Pyronnet S. Control of contact-inhibition by 4E-BP1 upregulation. Cell Cycle 2010; 9: 1241-1245.
37. Azar R, Alard A, Susini C, Bousquet C, Pyronnet S. 4E-BP1 is a target of Smad4 essential for TGFbeta-mediated inhibition of cell proliferation. EMBO J 2009; 28: 3514-3522.
38. Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE. Colorectal cancer: mutations in a signalling pathway. Nature 2005; 436: 792.
39. Azar R, Najib S, Lahlou H, Susini C, Pyronnet S. Phosphatidylinositol 3-kinase-dependent transcriptional silencing of the translational repressor 4E-BP1. Cell Mol Life Sci 2008; 65: 3110-3117.
40. Graff JR, Konicek BW, Carter JH, Marcusson EG. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 2008; 68: 631-644.
41. O'Reilly KE, Warycha M, Davies MA, Rodrik V, Zhou XK, Yee H, Polsky D, Pavlick AC, Rosen N, Bhardwaj N, Mills G, Osman I. Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res 2009; 15: 2872-2878.
42. Salehi Z, Mashayekhi F. Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer. Clin Biochem 2006; 39: 404-409.
43. Seki N, Takasu T, Sawada S, Nakata M, Nishimura R, Segawa Y, Shibakuki R, Hanafusa T, Eguchi K. Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma. Lung Cancer 2010; 70: 329-334.
44. Alain T, Sonenberg N, Topisirovic I. mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio. Oncotarget 2012; 3: 1491-1492.